Literature DB >> 16829221

Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae.

S Viguet-Carrin1, J P Roux1, M E Arlot1, Z Merabet1, D J Leeming2, I Byrjalsen2, P D Delmas3, M L Bouxsein4.   

Abstract

Collagen characteristics contribute to bone biomechanical properties. Yet, few studies have analyzed the independent contributions of bone mineral density (BMD) and post-translational modifications of type I collagen to whole bone strength. Thus, the aim of this study was to determine the relative contributions of BMD and both enzymatic and non-enzymatic collagen crosslink concentration to the biomechanical properties of human vertebrae. Nineteen L3 vertebrae were collected after necropsy (age 26-93; 10 males, 9 females). BMD of the vertebral body was measured by DXA, and the vertebrae were compressed to failure to assess the stiffness, failure load and work to fracture. After mechanical testing, the concentration of both enzymatic crosslinks pyridinoline (PYD), and deoxypyridinoline (DPD) as well as, and the non-enzymatic crosslinks pentosidine (PEN) were analyzed in trabecular and cortical bone by reversed-phase HPLC. The extent of aspartic acid isomerization of type I collagen C telopeptide (CTX) was evaluated by ELISA of native (alpha CTX) and isomerized (beta CTX) forms. BMD was significantly positively related with stiffness (R(2) = 0.74; P < 0.0001), failure load (R(2) = 0.69; P < 0.0001) and work to fracture (R(2) = 0.44; P = 0.002). Bivariate regression analysis showed no association between collagen traits and biomechanical properties. However, in a multiple regression model, BMD and trabecular PEN were both significantly associated with failure load and work to fracture (multiple R(2) = 0.83, P = 0.001 and R(2) = 0.67, P = 0.001, respectively). Similarly, BMD and trabecular alpha/beta CTX ratio were both associated with stiffness (multiple R(2) = 0.83, P = 0.015). These findings indicate that post-translational modifications of type I collagen have an impact on skeletal fragility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16829221     DOI: 10.1016/j.bone.2006.05.013

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  84 in total

Review 1.  Type 2 diabetes and bone fractures.

Authors:  Kendall F Moseley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-04       Impact factor: 3.243

Review 2.  Effects of bone matrix proteins on fracture and fragility in osteoporosis.

Authors:  Grażyna E Sroga; Deepak Vashishth
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

Review 3.  The role of the collagen matrix in skeletal fragility.

Authors:  Deepak Vashishth
Journal:  Curr Osteoporos Rep       Date:  2007-06       Impact factor: 5.096

Review 4.  Is bone quality associated with collagen age?

Authors:  D J Leeming; K Henriksen; I Byrjalsen; P Qvist; S H Madsen; P Garnero; M A Karsdal
Journal:  Osteoporos Int       Date:  2009-03-28       Impact factor: 4.507

5.  Accumulation of carboxymethyl-lysine (CML) in human cortical bone.

Authors:  Corinne J Thomas; Timothy P Cleland; Grazyna E Sroga; Deepak Vashishth
Journal:  Bone       Date:  2018-02-02       Impact factor: 4.398

Review 6.  Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging.

Authors:  Alexei Terman; Tino Kurz; Marian Navratil; Edgar A Arriaga; Ulf T Brunk
Journal:  Antioxid Redox Signal       Date:  2010-04       Impact factor: 8.401

Review 7.  How can bone turnover modify bone strength independent of bone mass?

Authors:  C J Hernandez
Journal:  Bone       Date:  2008-02-20       Impact factor: 4.398

8.  Biochemical characterization of major bone-matrix proteins using nanoscale-size bone samples and proteomics methodology.

Authors:  Grazyna E Sroga; Lamya Karim; Wilfredo Colón; Deepak Vashishth
Journal:  Mol Cell Proteomics       Date:  2011-05-23       Impact factor: 5.911

9.  Spinal deformity index in patients with type 2 diabetes.

Authors:  C Di Somma; M Rubino; A Faggiano; L Vuolo; P Contaldi; N Tafuri; N Tafuto; M Andretti; S Savastano; A Colao
Journal:  Endocrine       Date:  2012-12-11       Impact factor: 3.633

10.  Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.

Authors:  S Y Tang; M R Allen; R Phipps; D B Burr; D Vashishth
Journal:  Osteoporos Int       Date:  2008-10-11       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.